Glenmark's interim data from PMS Study on Favipiravir released
The study was conducted in patients with mild to moderate COVID-19
The study was conducted in patients with mild to moderate COVID-19
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Financial support is being provided as a grant from the Government of India
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Subscribe To Our Newsletter & Stay Updated